Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regeneron Pharmaceuticals Inc (REGN)  
$1,034.23 10.14 (0.99%) as of 4:30 Fri 7/5


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 104,690,000
Market Cap: 108.27(B)
Last Volume: 418,302 Avg Vol: 758,271
52 Week Range: $692.45 - $1071.19
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  150
Guru Rank Value     : 6.9
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 192,995 237,237 312,646 469,880
Total Sell Value $189,656,342 $231,855,596 $295,997,978 $406,115,303
Total People Sold 7 13 16 18
Total Sell Transactions 18 40 67 129
End Date 2024-04-07 2024-01-05 2023-07-07 2022-07-07

   
Records found: 2433
  Page 75 of 98  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Schleifer Leonard S CEO & President   •       •      –    2011-09-06 4 AS $63.01 $521,631 I/I (7,900) 0     -
   Schleifer Leonard S CEO & President   •       •      –    2011-09-06 4 A $0.00 $0 I/I 7,000 7,000     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2011-09-06 4 D $65.76 $325,972 D/D (4,957) 13,377     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2011-09-06 4 OE $24.00 $200,016 D/D 8,334 18,334     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2011-09-02 4 AS $64.00 $266,624 D/D (4,166) 10,000     -
   Aberman Michael S VP Strategy and Investor Relat   •       –      –    2011-09-02 4 OE $24.00 $99,984 D/D 4,166 14,166     -
   Vagelos P Roy Chairman of the Board   •       •      –    2011-09-02 4 AS $60.35 $5,439,674 D/D (88,955) 140,087     -
   Larosa Joseph J SVP Gen Counsel & Secretary   •       –      –    2011-09-01 4 A $0.00 $0 D/D 10,000 10,000     -
   Vagelos P Roy Chairman of the Board   •       •      –    2011-09-01 4 AS $60.00 $210,000 D/D (3,500) 229,042     -
   Vagelos P Roy Chairman of the Board   •       •      –    2011-08-31 4 D $60.96 $13,413,943 D/D (220,045) 232,542     -
   Vagelos P Roy Chairman of the Board   •       •      –    2011-08-31 4 OE $28.01 $8,753,125 D/D 312,500 452,587     -
   Goldberg Murray A SVP Finance and Admin CFO Trea   •       –      –    2011-08-16 4 AS $56.46 $364,333 D/D (6,409) 77,734     -
   Goldberg Murray A SVP Finance and Admin CFO Trea   •       –      –    2011-08-15 4 D $56.61 $486,337 D/D (8,591) 84,143     -
   Goldberg Murray A SVP Finance and Admin CFO Trea   •       –      –    2011-08-15 4 OE $11.64 $174,600 D/D 15,000 92,734     -
   Baker Charles A Director   –       •      –    2011-08-10 4 OE $28.81 $115,240 D/D 4,000 9,590     -
   Van Plew Daniel P SVP & General Mgr Industrial O   •       –      –    2011-08-04 4 OE $20.90 $99,986 D/D 4,784 4,784     -
   Powchik Peter SVP Clinical Development   •       –      –    2011-08-01 4 OE $15.64 $236,852 D/D 15,144 15,144     -
   Goldberg Murray A SVP Finance and Admin CFO Trea   •       –      –    2011-07-28 4 AS $52.76 $531,323 D/D (9,705) 77,734     -
   Goldberg Murray A SVP Finance and Admin CFO Trea   •       –      –    2011-07-27 4 D $53.18 $651,880 D/D (12,258) 87,439     -
   Goldberg Murray A SVP Finance and Admin CFO Trea   •       –      –    2011-07-27 4 OE $9.49 $208,429 D/D 21,963 99,697     -
   Powchik Peter SVP Clinical Development   •       –      –    2011-07-26 4 AS $54.74 $602,491 D/D (10,977) 0     -
   Powchik Peter SVP Clinical Development   •       –      –    2011-07-25 4 D $56.26 $788,934 D/D (14,023) 10,977     -
   Powchik Peter SVP Clinical Development   •       –      –    2011-07-25 4 OE $15.64 $391,000 D/D 25,000 25,000     -
   Roberts William VP Regulatory Development and   •       –      –    2011-07-14 4 AS $56.43 $6,237 I/I (110) 3,647     -
   Vagelos P Roy Chairman of the Board   •       •      –    2011-07-14 4 AS $56.43 $37,313 I/I (658) 160,000     -
  2433 Records found
  Previous  70  71  72  73  74  75  76  77  78  79  Next   
  Page 75 of 98
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us